Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01529034 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

A Phase 3 study, sponsored by UCB Biopharma S.P.R.L..

Terminated
Registry status
Phase 3
Development phase
175
Enrollment target

NCT01529034: Clinical Trial Phase 3 study, sponsored by UCB Biopharma S.P.R.L..

NCT01529034 is a Phase 3 study that was terminated before completion, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 175 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01529034, a Phase 3 study, was terminated before completion, sponsored by UCB Biopharma S.P.R.L..

TERMINATED
Registry status
Phase 3
Development phase
175 participants
Enrollment target

Study Summary

The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.

Primary Outcome

Duration of participant study participation for collection of long term safety data

Interventions

  • DRUG USL261

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2012-07
Phase Phase 3
UCB Biopharma S.P.R.L.

23 total trials

Why NCT01529034 stopped before completion

NCT01529034 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).

The record links to 0 conditions, and to 1 intervention - of which USL261 is the first listed.

NCT01529034 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01529034 about?

NCT01529034 is a clinical study titled "Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters". The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.

What is the current status of trial NCT01529034?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2012-07.

What interventions are being tested in trial NCT01529034?

The interventions under investigation include: USL261 (DRUG).

Who is sponsoring clinical trial NCT01529034?

This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01529034's enrollment target sits among peer trials

175 1440th of 2000 higher than 559 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04722341 · 175 participants · NA

    Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

  • NCT05094037 · 175 participants · NA

    Orthotic Treatment of Diabetic Foot Ulcers

  • NCT05165745 · 175 participants · NA

    Stick2PrEP Cisgender Women and Trans Individuals

  • NCT05312255 · 175 participants · NA

    Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01529034, the US trial registry maintained by the National Library of Medicine. NCT01529034 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.